Početna › Melanom › Massachusetts › Boston
Kliničke studije za Melanom u gradu Boston, MA
26 studija za Melanom traži sudionike na lokacijama u gradu Boston i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
U tijeku regrutacijaFaza 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
U tijeku regrutacijaFaza 2
- Local Institution - 0124, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
U tijeku regrutacijaFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
U tijeku regrutacijaFaza 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
U tijeku regrutacijaFaza 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
U tijeku regrutacijaOpažajna studija
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
U tijeku regrutacijaFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
U tijeku regrutacijaFaza 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
U tijeku regrutacija
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
U tijeku regrutacijaFaza 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
U tijeku regrutacijaFaza 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
U tijeku regrutacijaFaza 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
U tijeku regrutacijaFaza 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
U tijeku regrutacijaFaza 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
U tijeku regrutacijaFaza 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
U tijeku regrutacijaFaza 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
U tijeku regrutacijaFaza 2
- Dana Farber Cancer Institute, Boston
Studije za Melanom u drugim gradovima
- Houston, TX59 studija
- New York City, NY38 studija
- Los Angeles, CA34 studija
- Nashville, TN33 studija
- Pittsburgh, PA31 studija
- Philadelphia, PA23 studija
- San Francisco, CA22 studija
- Durham, NC21 studija
- Atlanta, GA21 studija
- St. Louis, MO21 studija
- Salt Lake City, UT21 studija
- Columbus, OH21 studija
Ostale studije u gradu Boston
- Rak dojke111 studija
- Nemikrocelularni karcinom pluća90 studija
- Rak (sve vrste)86 studija
- Kolorektalni rak63 studija
- Metastatski karcinom63 studija
- Rak pluća62 studija
- Rak jajnika61 studija
- Rak prostate59 studija
- Depresija52 studija
- Rak endometrija50 studija
- Srčano zatajenje44 studija
- Akutna mijeloična leukemija44 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.